Biotechnology Business

ImmuneRegen BioSciences Signs Material Transfer Agreement with Celgene Cellular Therapeutics

Published in Oncology Business Week, February 10th, 2008

ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), announced it has finalized a Material Transfer Agreement (MTA) with Celgene Cellular Therapeutics (CCT). As part of the agreement, ImmuneRegen will ship its potential therapeutic Homspera(R) to CCT for testing.

Addressing existing complementary product pipelines; Celgene Cellular Therapeutics and ImmuneRegen are exploring opportunities to jointly pursue U.S. government funding in support of their rapid wound healing applications.

CCT will perform testing of Homspera in order to evaluate the potential impact on cellular products in the company's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2008-02-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry